Fennec Pharmaceuticals Inc • FENC

Capital at risk.

About Fennec Pharmaceuticals Inc
Ticker
info
FENC
Trading on
info
NASDAQ
ISIN
info
CA31447P1009
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Jeffrey S. Hackman
Headquarters
info
68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709
Employees
info
32
Website
info
https://fennecpharma.com
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Metrics
BasicAdvanced
Market cap
info
$269M
P/E ratio
info
-
EPS
info
-$0.26
Dividend Yield
info
0.00%
Beta
info
0.81
Forward P/E ratio
info
12.29
EBIDTA
info
$-4.3M
Ex dividend date
info
-
Price & volume
Market cap
info
$269M
Average daily volume
info
0.1M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
12.29
PEG ratio
info
1.47
Trailing P/E
info
0
Price to sales
info
6.95
Price to book
info
57.93
Earnings
EPS
info
-$0.26
EPS estimate (current quarter)
info
-$0.03
EPS estimate (next quarter)
info
$0.20
EBITDA
info
$-4.3M
Revenues (TTM)
info
$38.8M
Revenues per share (TTM)
info
$1.41
Technicals
Beta
info
0.81
52-week High
info
$9.92
52-week Low
info
$4.68
50-day moving average
info
$7.94
200-day moving average
info
$8.28
Short ratio
info
7.11
Short %
info
3.17%
Management effectiveness
ROE (TTM)
info
-1,005.59%
ROA (TTM)
info
-5.39%
Profit margin
info
-17.89%
Gross profit margin
info
$36.1M
Operating margin
info
-1.52%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
78.70%
Share stats
Outstanding Shares
info
34.2M
Float
info
13.2M
Insiders %
info
14.17%
Institutions %
info
53.26%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 5 analysts.

Average price target

info
$15.33
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.06
-$0.13
53.85%
Q4 • 24Beat
-$0.04
-$0.10
60.00%
Q1 • 25Beat
-$0.11
-$0.04
-175.00%
Q2 • 25Missed
-$0.02
$0.07
-128.57%
Q3 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$9.7M
$-3.2M
-32.66%
Q2 • 25
$12.5M
$-0.6M
-5.12%
Q3 • 25
29.11%
-79.76%
-84.32%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$44.9M
$52.3M
116.63%
Q2 • 25
$49.2M
$53.7M
109.12%
Q3 • 25
9.66%
2.60%
-6.44%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-3.7M
-
$-0.3M
$-3.7M
Q2 • 25
$1.5M
-
$1.7M
$1.5M
Q3 • 25
-140.50%
-
-715.85%
-140.50%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Fennec Pharmaceuticals Inc share?
Collapse

Fennec Pharmaceuticals Inc shares are currently traded for undefined per share.

How many shares does Fennec Pharmaceuticals Inc have?
Collapse

Fennec Pharmaceuticals Inc currently has 34.2M shares.

Does Fennec Pharmaceuticals Inc pay dividends?
Collapse

No, Fennec Pharmaceuticals Inc doesn't pay dividends.

What is Fennec Pharmaceuticals Inc 52 week high?
Collapse

Fennec Pharmaceuticals Inc 52 week high is $9.92.

What is Fennec Pharmaceuticals Inc 52 week low?
Collapse

Fennec Pharmaceuticals Inc 52 week low is $4.68.

What is the 200-day moving average of Fennec Pharmaceuticals Inc?
Collapse

Fennec Pharmaceuticals Inc 200-day moving average is $8.28.

Who is Fennec Pharmaceuticals Inc CEO?
Collapse

The CEO of Fennec Pharmaceuticals Inc is Jeffrey S. Hackman.

How many employees Fennec Pharmaceuticals Inc has?
Collapse

Fennec Pharmaceuticals Inc has 32 employees.

What is the market cap of Fennec Pharmaceuticals Inc?
Collapse

The market cap of Fennec Pharmaceuticals Inc is $269M.

What is the P/E of Fennec Pharmaceuticals Inc?
Collapse

The current P/E of Fennec Pharmaceuticals Inc is null.

What is the EPS of Fennec Pharmaceuticals Inc?
Collapse

The EPS of Fennec Pharmaceuticals Inc is -$0.26.

What is the PEG Ratio of Fennec Pharmaceuticals Inc?
Collapse

The PEG Ratio of Fennec Pharmaceuticals Inc is 1.47.

What do analysts say about Fennec Pharmaceuticals Inc?
Collapse

According to the analysts Fennec Pharmaceuticals Inc is considered a buy.